Atrium Therapeutics reports Q1 collaboration revenue $19.6M, driven by $15M BMS milestone; cash $267.8M

Atrium Therapeutics, Inc.

Collaboration revenue $19.6M in Q1 2026, primarily a $15M milestone from BMS partnership.
R&D expenses $16.7M, G&A $20.3M; cash and equivalents $267.8M.
ATR 1072 IND submission planned for H2 2026; pre-IND discussions with FDA/Health Canada completed.
Company launched as independent public on Feb 27, 2026 after spin-off from Avidity.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.